Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELDNNASDAQ:INMBNASDAQ:KRRONASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELDNEledon Pharmaceuticals$3.47-3.9%$4.15$1.52▼$5.54$207.29M0.8274,537 shs254,739 shsINMBINmune Bio$8.86+6.7%$8.34$4.32▼$12.72$235.60M1.93239,763 shs202,104 shsKRROKorro Bio$20.38-15.2%$29.27$18.50▼$98.00$191.35M2.1387,918 shs93,835 shsTNXPTonix Pharmaceuticals$29.77-2.4%$18.68$6.76▼$1,146.01$55.64M2.23687,968 shs1.90 million shsUnlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELDNEledon Pharmaceuticals+2.85%-0.55%-15.85%-15.46%+79.60%INMBINmune Bio+2.22%+8.21%-3.38%+84.86%-31.97%KRROKorro Bio+1.14%-4.11%-8.60%-44.50%-63.04%TNXPTonix Pharmaceuticals+32.48%+87.41%+232.72%-20.81%-97.24%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELDNEledon Pharmaceuticals1.847 of 5 stars3.53.00.00.01.01.70.0INMBINmune Bio1.7464 of 5 stars3.60.00.00.02.21.70.6KRROKorro Bio1.2292 of 5 stars3.61.00.00.01.90.00.0TNXPTonix Pharmaceuticals2.2816 of 5 stars3.52.00.00.01.11.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELDNEledon Pharmaceuticals 3.00Buy$12.50260.23% UpsideINMBINmune Bio 3.17Buy$22.80157.34% UpsideKRROKorro Bio 3.14Buy$142.57599.57% UpsideTNXPTonix Pharmaceuticals 3.00Buy$585.001,865.07% UpsideCurrent Analyst Ratings BreakdownLatest TNXP, INMB, KRRO, and ELDN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/20/2025KRROKorro BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$115.00 ➝ $115.003/20/2025TNXPTonix PharmaceuticalsNoble FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$70.00 ➝ $70.003/19/2025KRROKorro BioRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$105.00 ➝ $95.002/13/2025INMBINmune BioMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $30.002/11/2025INMBINmune BioScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$22.00 ➝ $23.001/28/2025ELDNEledon PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.001/28/2025INMBINmune BioRODMAN&RENSHAWSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy1/28/2025INMBINmune BioRodman & RenshawSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$23.001/10/2025KRROKorro BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$155.00(Data available from 3/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELDNEledon PharmaceuticalsN/AN/AN/AN/A$0.30 per shareN/AINMBINmune Bio$42K5,609.43N/AN/A$2.07 per share4.28KRROKorro Bio$2.27M84.26N/AN/A$21.19 per share0.96TNXPTonix Pharmaceuticals$10.09M5.51N/AN/A$5,751.80 per share0.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELDNEledon Pharmaceuticals-$116.54M-$2.01N/AN/AN/AN/A-189.99%-28.17%3/27/2025 (Estimated)INMBINmune Bio-$30.01M-$2.18N/AN/AN/AN/A-117.48%-78.96%3/27/2025 (Estimated)KRROKorro Bio-$81.17M-$9.39N/AN/AN/AN/A-50.25%-38.48%3/25/2025 (Estimated)TNXPTonix Pharmaceuticals-$116.66M-$2,535.85N/AN/AN/A-1,197.86%-163.95%-118.88%4/7/2025 (Estimated)Latest TNXP, INMB, KRRO, and ELDN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/7/2025N/ATNXPTonix Pharmaceuticals-$6.23N/AN/AN/A$3.35 millionN/A3/27/2025N/AINMBINmune Bio-$0.54N/AN/AN/AN/AN/A3/20/2025Q4 2024ELDNEledon Pharmaceuticals-$0.32-$0.64-$0.32-$0.64N/AN/A3/18/2025Q4 2024KRROKorro Bio-$2.33-$2.26+$0.07-$2.26N/A$2.27 million3/18/2025Q4 2024TNXPTonix Pharmaceuticals-$6.23-$9.77-$3.54-$9.77$3.20 million$2.58 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/AKRROKorro BioN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELDNEledon PharmaceuticalsN/A6.536.53INMBINmune BioN/A2.592.59KRROKorro BioN/A11.2311.23TNXPTonix Pharmaceuticals0.073.332.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELDNEledon Pharmaceuticals56.77%INMBINmune Bio12.72%KRROKorro Bio13.18%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipELDNEledon Pharmaceuticals11.70%INMBINmune Bio35.20%KRROKorro Bio5.40%TNXPTonix Pharmaceuticals0.04%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELDNEledon Pharmaceuticals1059.74 million52.75 millionOptionableINMBINmune Bio1026.59 million14.37 millionOptionableKRROKorro Bio709.39 million8.86 millionNo DataTNXPTonix Pharmaceuticals501.87 million1.87 millionNot OptionableTNXP, INMB, KRRO, and ELDN HeadlinesRecent News About These CompaniesTonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 39.5% - Should You Buy?March 25 at 2:48 PM | marketbeat.comTonix Pharmaceuticals: FDA AdCom News Positive, But Making Bull Case Is ProblematicMarch 25 at 1:28 PM | seekingalpha.comPharma Frenzy: Volatility Ignites Biotech Sector (TNXP)March 25 at 9:10 AM | marketbeat.comTonix says FDA will not require committee meeting for TNX-102 SL NDAMarch 24 at 10:40 PM | markets.businessinsider.comTonix Pharmaceuticals stock soars on FDA updateMarch 24 at 12:38 PM | investing.comWhy Tonix Pharmaceuticals (TNXP) Stock Is RisingMarch 24 at 12:38 PM | benzinga.comTonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025 for Fibromyalgia Treatment TNX-102 SLMarch 24 at 8:40 AM | quiverquant.comTonix Pharma’s TNX-102 SL Advances in FDA ProcessMarch 24 at 8:40 AM | tipranks.comTonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of FibromyalgiaMarch 24 at 8:00 AM | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Given Outperform Rating at Noble FinancialMarch 22 at 3:13 AM | americanbankingnews.comWhy Tonix Pharmaceuticals Holding Corp.’s (TNXP) Stock Is Up 16.43%March 21, 2025 | aaii.comWhy Tonix Pharmaceuticals Holding Corp.’s (TNXP) Stock Is Up 10.44%March 21, 2025 | aaii.comAs Mpox Cases Spread Around the World, Tonix Pharmaceuticals’ Single-Dose Vaccine TNX-801 Has Potential to Slow the SpreadMarch 20, 2025 | finance.yahoo.comAs Mpox Cases Spread Around the World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has ...March 20, 2025 | gurufocus.comAs Mpox Cases Spread Around The World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has Potential To Slow The SpreadMarch 20, 2025 | benzinga.comAs Mpox Cases Spread Around the World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has Potential to Slow the SpreadMarch 20, 2025 | accessnewswire.comTonix Pharmaceuticals Shares Fall on Lower 4Q Revenue, Net LossMarch 19, 2025 | marketwatch.comTonix Pharma drops after Q4 revenue missMarch 19, 2025 | msn.comTonix Pharmaceuticals Stock Dives After Q4 Earnings Miss, But Retail’s Feeling BullishMarch 19, 2025 | msn.comAbsci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionMarch 19, 2025 | benzinga.comTonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational HighlightsMarch 19, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNXP, INMB, KRRO, and ELDN Company DescriptionsEledon Pharmaceuticals NASDAQ:ELDN$3.47 -0.14 (-3.88%) Closing price 04:00 PM EasternExtended Trading$3.46 -0.01 (-0.14%) As of 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.INmune Bio NASDAQ:INMB$8.86 +0.56 (+6.75%) Closing price 04:00 PM EasternExtended Trading$8.85 -0.01 (-0.17%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Korro Bio NASDAQ:KRRO$20.38 -3.65 (-15.19%) Closing price 04:00 PM EasternExtended Trading$21.39 +1.01 (+4.96%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Tonix Pharmaceuticals NASDAQ:TNXP$29.77 -0.74 (-2.43%) Closing price 04:00 PM EasternExtended Trading$29.43 -0.34 (-1.14%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Insiders Sell: This Is What It Means for the Market Oklo’s Stock Price Meltdown Is an Opportunity to Buy Top Dividend Stocks With Over 10 Years of Hikes—and Room to Grow Quantum Gamble? Is IonQ's Stock an Opportunity or a Mirage? Will CrowdStrike's FedRAMP Authorization Move CRWD Stock? Top 3 Insider Stock Buys in March—Are They Still Good in April? Taiwan Semiconductor Attracts Big Money on NVIDIA Chip Growth D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
